Literature DB >> 17945453

Structural elucidation of rabeprazole sodium photodegradation products.

Cássia V Garcia1, Norma S Nudelman, Martin Steppe, Elfrides E S Schapoval.   

Abstract

Rabeprazole sodium is a proton pump inhibitor, used in acid-related disorders, like peptic ulcers and gastroesophageal reflux. It is known to be an acid-labile drug, however, few data about its stability under other factors are available. The aim of this work was to study the photodegradation of rabeprazole, to determine its kinetics and to elucidate the structures of the main degradation products. UVC-254 nm and metal-halide lamps were used. The analysis of the samples was carried out by HPLC. When the drug was in methanol solution, one main degradation product was formed; the degradation rate followed zero-order kinetics. The (1)H and (13)C NMR spectroscopic determinations revealed the product was the benzimidazolone. Another isolated product was identified as benzimidazole. The latter was confirmed against an authentic sample. A third photodegradation product was identified as the [4-(3-methoxy-propoxy)-3-methyl-pyridin-2-yl]methanol, by (1)H and (13)C NMR of the reaction mixture in chloroform-d. When powdered commercial tablets were exposed to UVC irradiation, they showed the same degradation products along with other unidentified, which appeared as traces; the degradation rate was slower than in solution. The intact tablets were stable after 50 days of exposition to the same light source.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945453     DOI: 10.1016/j.jpba.2007.09.002

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Photodegradation of fleroxacin injection: II. Kinetics and toxicological evaluation.

Authors:  Wei Li; Jun Wang; Yu-Zhu Hu
Journal:  AAPS PharmSciTech       Date:  2013-03-06       Impact factor: 3.246

2.  Stability-indicating HPLC-DAD methods for determination of two binary mixtures: Rabeprazole sodium-mosapride citrate and rabeprazole sodium-itopride hydrochloride.

Authors:  Hamed M El-Fatatry; Mokhtar M Mabrouk; Ismail I Hewala; Ehab H Emam
Journal:  J Pharm Anal       Date:  2013-09-23

3.  Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Process-Related Impurities and Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation.

Authors:  Navneet Kumar; Dhanaraj Sangeetha
Journal:  Sci Pharm       Date:  2013-03-17

4.  Validation and application of a new reversed phase HPLC method for in vitro dissolution studies of rabeprazole sodium in delayed-release tablets.

Authors:  Md Saddam Nawaz
Journal:  J Anal Methods Chem       Date:  2013-08-22       Impact factor: 2.193

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.